medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2016, Number 03

<< Back Next >>

Ginecol Obstet Mex 2016; 84 (03)

Metaplastic carcinoma of the breast and the impact of the p63 and cytokeratin 5/6: experience of 40 patients

Sherwell-Cabello, Santiago; Maffuz-Aziz, Antonio; Hernández-Hernández, Betsabé; Bautista-Piña, Verónica; Labastida-Almendaro, Sonia; Rodríguez-Cuevas, Sergio

Language: Spanish
References: 22
Page: 127-135
PDF size: 313.87 Kb.


ABSTRACT

Background: Metaplasic carcinoma of the breast was initially described by Huvos in 1974. It is a rare and aggressive entity characterized by the presence of mesenchymal and epithelial components.
Objetive: To know the incidence and biologic behaviour of the metaplasic carcinoma of the breast at the Instituto de Enfermedades de la Mama, FUCAM, AC.
Methods: Data on women diagnosed with metaplasic carcinoma of the breast between January 2005 and December 2014 was collected by retrospectively reviewing in FUCAM. Clinical, pathological and immunohistochemical characteristics were assessed. The five-year disease-free survival (DFS) and overall survival (OS) were evaluated.
Results: a total of 4198 patients have been diagnosed with breast cancer in our institution, 40 (0.95%) of them with metaplasic carcinoma. The median age of the patients was 46 years (27-73). 60% of the patients were diagnosed with an advanced clinical stage (III) and the triple-negative subtype was the most frequently found. A mean follow-up of 24 months showed rates of overall survival and disease-free survival of 80% and 69.9%, respectively. The presence of both, cytokeratins 5/6 and p63, seems to have a negative impact in local recurrence.
Conclusion: this study demonstrates that metaplasic carcinoma is a rare and aggressive disease. Expression of both tumor cytokeratins was associated with a worse outcome.


REFERENCES

  1. Cardenas-Sanchez J, Bargallo-Rocha E, Erazo-Valle A, Maafs-Molina E, Poitevin-Chacon A. Epidemiología del cáncer mamario en México. In: Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario. Colima: Mason Doyma; 2013; p. 5-6.

  2. Breast Cancer Organization. Breast cancer 2015. Invasive Ductal Carcinoma (consultado 2015 Jul 7). Disponible en http://www.breastcancer.org/symptoms/types/idc

  3. Nam J, Marks L. Radiotherapy techniques. In: Bland KI, Copeland EM, editors. The Breast: Comprehensive Management of Benign and Malignant Diseases. 4th ed. Saunders ELSERVIER Philadelphia: 2009; p. 1053-1054.

  4. Page DL, Anderson TJ, Sakamoto G: Infiltrating carcinoma: Major histological types. In Page DL, Anderson TJ (eds): Diagnostic histopathology of the breast. Edinburgh, Churchill Livingstone, 1987.

  5. Huvos AG, Lucas JC Jr, Foote FW Jr. Metaplastic breast carcinoma: rare form of mammary cancer. N Y State J Med 1973, 73:1078–1082.

  6. Koker MM, Kleer CG. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol 2004; 28: 1506-12.

  7. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010; 347-376.

  8. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24: 2206-23.

  9. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD: A new histologic grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003, 12:320-327.

  10. Nelson RA, Guye ML, Luu T, Lai LL. Survival outcomes of metaplastic breast cancer patients: results from a US population- based analysis. Ann Surg Oncol. 2015; 22(1):24–31.

  11. Paul Wright G, Davis AT, Koehler TJ, Melnik MK, Chung MH. Hormone receptor status does not affect prognosis in metaplastic breast cancer: a population-based analysis with comparison to infiltrating ductal and lobular carcinomas. Ann Surg Oncol. 2014;21:3497–503.

  12. Jung SY, Kim HY, Nam BH, Min SY, Lee SJ, Park C, et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat. 2010;120:627–37.

  13. Kuroda N, Fujishima N, Inoue K, Ohara M, Hirouchi T, Mizuno K, et al. Basal-like carcinoma of the breast: further evidence of the possibility that most metaplastic carcinomas may be actually basal-like carcinomas. Med Mol Morphol. 2008;41:117–120.

  14. Tseng WH, Martinez SR. Metaplastic breast cancer: to radiate or not to radiate? Ann Surg Oncol. 2011; 18(1): 94–103.

  15. Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National cancer data Base. Ann Surg Oncol. 2007;14:166–73.

  16. Luini A, Aguilar M, Gatti G, Fasani R, Botteri E, Brito JA, et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat. 2007;101:349–53.

  17. Hennessy BT, Giordano S, Broglio K, Duan Z, Trent J, Buchholz TA, et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol. 2006;17:605–13.

  18. Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999;10:413–9. doi: 10.1023/A:1008329910362.

  19. Okada N, Hasebe T, Iwasaki M, et al. Metaplastic carcinoma of the breast. Hum Pathol. 2010;41(7):960–970.

  20. Reisenbichler ES, Lester SC, Richardson AL, Dillon DA, Ly A, Brock JE. Interobserver concordance in implementing the 2010 ASCO/ CAP recommendations for reporting ER in breast carcinomas: a demonstration of the difficulties of consistently reporting low levels of ER expression by manual quantification. Am J Clin Pathol. 2013; 140: 487-494.

  21. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10(16): 5367–5374

  22. Leibl S, Moinfar F. Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol. 2005;58:700–704.




2020     |     www.medigraphic.com